The identification and treatment of human papillomavirus (HPV) infections and HPV-associated neoplasm are complex. Difficulties in diagnosis and treatment of HPV-associated diseases arise from inabilities to detect HPV efficiently, the lack of specific antiviral drugs active against HPV and the high rates of recurrence and persistence of HPV infections after treatment. We present a review of therapies for HPV infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4067/s0716-10182007000300006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Management of women with abnormal cervical cytology: Update of INCa recommendations after the implementation of HPV screening].
Gynecol Obstet Fertil Senol
February 2025
Service de gynécologie obstétrique, hôpital Nord, CHU de Marseille, chemin des Bourrely, 13015 Marseille, France. Electronic address:
Objective: To update the recommendations issued by the National Cancer Institute (INCa) on the management of women with abnormal cervical cytology.
Methods: INCa recommendations on the management of women with abnormal cervical cytology were published in 2016. In 2019, the High Authority of Health (HAS) recommends HPV test for cervical cancer screening in women over 30.
'Does human papillomavirus (HPV) cause cancer?' - A cross-sectional study of HPV awareness among sexual minority men in Nigeria.
Sex Health
January 2025
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Background Human papillomavirus (HPV)-associated cancers are a global concern, particularly for sexual minority men (SMM). Understanding awareness and the determinants of these beliefs is crucial for developing educational programs to reduce HPV-associated cancers. This study explored awareness and determinants of beliefs about HPV's carcinogenicity among SMM living with and without HIV in Nigeria.
View Article and Find Full Text PDFUnderstanding the vaginal microbiome among women with different genotypes of human papillomavirus infection in remote Andaman islands.
Front Cell Infect Microbiol
January 2025
Indian Council of Medical Research - Regional Medical Research Centre, Port Blair, Andaman and Nicobar Islands, India.
Background: Human papillomavirus (HPV) is a viral infection, and its acquisition and persistence are significantly influenced by the vaginal microbiota. Understanding and comparing the vaginal microbiome of HPV infected women in Andaman and Nicobar Islands is crucial.
Methods: The study involved collecting vaginal swabs and extracting DNA using the QIAamp DNA Minikit.
Vulvar inspection at the time of cervical cancer screening: European Society of Gynaecological Oncology (ESGO), International Society for the Study of Vulvovaginal Disease (ISSVD), European College for the Study of Vulval Disease (ECSVD), and European Federation for Colposcopy (EFC) consensus statements.
Int J Gynecol Cancer
January 2025
Hacettepe University, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Ankara, Turkey.
Background: Vulvar squamous cell carcinoma incidence is increasing, especially among women under 60, largely attributed to human papillomavirus infections. Precursor pre-invasive vulvar lesions are frequently underdiagnosed. Routine vulvar inspection during cervical cancer screening could offer an opportunity for the detection of these lesions.
View Article and Find Full Text PDFOutcomes and associated factors of cervical human papillomavirus infection among 608 women in Shenzhen, China, 2018-2023.
Front Public Health
January 2025
Clinical Medical College of Shenzhen, Guangzhou University of Chinese Medicine, Shenzhen, China.
Objective: This study aimed to uncover the patterns of Human papillomavirus (HPV) infection outcomes in women and assess the risk factors that may affect these outcomes.
Methods: A retrospective study was conducted on 608 women who tested positive for HPV-DNA during their initial visit to the outpatient department of Shenzhen Longgang Central Hospital from 2018 to 2023 and who had subsequent HPV-DNA testing as part of their post-visit monitoring. The monitoring intervals were every 6 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!